Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0224543B2 - - Google Patents
[go: Go Back, main page]

JPH0224543B2 - - Google Patents

Info

Publication number
JPH0224543B2
JPH0224543B2 JP57138019A JP13801982A JPH0224543B2 JP H0224543 B2 JPH0224543 B2 JP H0224543B2 JP 57138019 A JP57138019 A JP 57138019A JP 13801982 A JP13801982 A JP 13801982A JP H0224543 B2 JPH0224543 B2 JP H0224543B2
Authority
JP
Japan
Prior art keywords
polymer
organopolysiloxane
group
nhcoo
segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP57138019A
Other languages
Japanese (ja)
Other versions
JPS5928968A (en
Inventor
Masao Kato
Teruo Takakura
Masaaki Yamabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd filed Critical Asahi Glass Co Ltd
Priority to JP57138019A priority Critical patent/JPS5928968A/en
Publication of JPS5928968A publication Critical patent/JPS5928968A/en
Publication of JPH0224543B2 publication Critical patent/JPH0224543B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Materials For Medical Uses (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は抗凝血性材料に関するものである。 人工臓器、人工血管、輸血装置のごとく血液に
直接接触して使用される医用器材の構成材料とし
て抗凝血性材料がもとめられている。従来かかる
材料としての種々の高分子材料が提案され、一部
実用にも供せられてきているが、従来の材料にお
いては、抗凝血性が未だ不充分であつたり、その
耐久性が低かつたり、機械的強度が乏しかつたり
あるいは成形が困難であるなどの難点があつた。 また、抗凝血性を有し、かつ特定の使用目的に
対する特殊な機能を付与した材料に関する研究例
は少ない。例えば、人工肺用膜を目的とした抗凝
血性を有しかつ、ガス透過性の大きい材料に関す
る報告はない。 本発明者らは上記問題点の認識のもとに鋭意研
究を重ねた結果、特定の構造を有しオルガノポリ
シロキサンセグメントと含フツ素セグメントを含
むセグメント化ポリマーが、抗凝血性および耐久
性機械的強度、成形性の点で優れ、かつシロキサ
ン含量を調節することで酸素透過性の大きい材料
ともなり得ることを見出した。 かくして、本発明は上記知見に基いて完成され
たものであり、オルガノポリシロキサンセグメン
トと含フツ素セグメントが主鎖に規則的に組込ま
れたセグメント化ポリマーからなる抗凝血性材料
を新規に提供するものである。 本発明においては、セグメント化ポリマーがオ
ルガノポリシロキサンセグメントと含フツ素セグ
メントからなり、両セグメントが主鎖に規則的に
組込まれていることが重要である。 かかるセグメント化ポリマーは、ミクロ相分離
構造を有するため優れた抗凝血性が発現され、含
フツ素セグメントの寄与により耐久性、生体適合
性に優れており、かつオルガノポリシロキサンセ
グメントの寄与により酸素透過性の大きな材料と
なる。 また、溶剤溶解性に優れコーテイング法による
適用が容易であるなどの成形面での利点があり、
さらに機械的強度の面でも優れている。 これに対して、オルガノポリシロキサンセグメ
ントを有するポリマーであつてもグラフト共重合
体のように主鎖に規則的に組込まれていないもの
はミクロ相分離構造の形成が困難となり、抗凝血
性の点で不充分となるばかりでなく、耐久性、機
械的強度などの点でも劣るものとなる。 また、含フツ素セグメントが含まれない場合に
おいては、耐久性、生体適合性などの点で劣り、
オルガノポリシロキサンセグメントを含まない場
合は酸素透過性などの点で劣るものとなるので好
ましくない。 本発明において、セグメントポリマーとして
は、ビニル化合物のラジカル重合、イオン重合、
配位重合、あるいは二官能性モノマーの重縮合、
重付加、さらにはエポキシドなどの開環重合など
種々の方法によつて得られるものが使用可能であ
るが、オルガノポリシロキサンセグメントと含フ
ツ素セグメントとの配列の規制が完全に行われ、
再現性よく目的とする重合体を得ることが可能で
あるという点から、オルガノポリシロキサンセグ
メントと含フツ素セグメントとが規則的に配列さ
れたプレポリマーに鎖延長剤を作用せしめて得ら
れる重縮合物もしくは重付加物が好ましく採用可
能である。 かかる好適なセグメント化ポリマーにおける結
合様式としては、ポリウレタン、ポリウレタンウ
レア、ポリウレア、ポリエステル、ポリアミド、
ポリアミドイミド、ポリイミド、ポリカーボナー
ト、ポリエーテルスルホン型など種々の形態のも
のが採用可能であるが、重合体の耐久性、機械的
特性、生体適合性などの点からポリウレタン、ポ
リウレタンウレアおよびポリウレア型の結合様式
が好ましい。 また、ポリマーに親水性を与えかつ強度を増す
ために第3セグメントとして、オキシアルキレン
鎖を導入することが可能である。オキシアルキレ
ン鎖は、オルガノポリシロキサンセグメントのか
わりに含フツ素セグメントと規則的に配列させポ
リマー中に導入することが好ましい。 かかるセグメント化ポリマーは、繰返し単位と
して (a) (−RNHCONHCH2RfCH2NHCOO−A−OCONHCH2RfCH2NH
CONH)− および () (b) (−RNHCONHCH2RfCH2NHCOO−B−CONHCH2RfCH2NHC
ONH)− (a) (−R−OCONHCH2RfCH2NHCOO−A−OCONHCH2RfCH2
NHCONH)− および () (b) (−R−OCONHCH2RfCH2NHCOO−B−CONHCH2RfCH2N
HCONH)− (a) (−RNHCONHCH2RfCH2NHCONH−A−NHCONHCH2RfCH2
NHCONH)− および () (b) (−RNHCONHCH2RfCH2NHCOO−B−CONHCH2RfCH2NHC
ONH)− などが例示され、中でも一般式()で表わされ
るものは耐久性、機械的特性、原料の入手性など
の面から特に好適である。 上記一般式において、Rはナシあるいは炭素数
1〜20、好ましくは1〜10の2価の有機基であ
り、具体的には(−CH2)−1(1=1〜10)、
The present invention relates to anticoagulant materials. BACKGROUND ART Anticoagulant materials are in demand as constituent materials for medical equipment used in direct contact with blood, such as artificial organs, artificial blood vessels, and blood transfusion devices. Various polymeric materials have been proposed as such materials, and some of them have been put into practical use, but the conventional materials still have insufficient anticoagulability, low durability, and However, there were disadvantages such as poor mechanical strength, stiffness, and difficulty in molding. In addition, there are few examples of research on materials that have anticoagulant properties and have special functions for specific purposes. For example, there are no reports regarding materials with anticoagulant properties and high gas permeability intended for membranes for oxygenators. The present inventors have conducted intensive research based on the recognition of the above problems, and have found that a segmented polymer having a specific structure and containing an organopolysiloxane segment and a fluorine-containing segment has anticoagulant properties and durable mechanical properties. It has been found that the material has excellent mechanical strength and moldability, and can also be made into a material with high oxygen permeability by adjusting the siloxane content. Thus, the present invention has been completed based on the above findings, and provides a novel anticoagulant material comprising a segmented polymer in which organopolysiloxane segments and fluorine-containing segments are regularly incorporated into the main chain. It is something. In the present invention, it is important that the segmented polymer consists of an organopolysiloxane segment and a fluorine-containing segment, and that both segments are regularly incorporated into the main chain. Such segmented polymers exhibit excellent anticoagulant properties due to their microphase-separated structure, excellent durability and biocompatibility due to the contribution of fluorine-containing segments, and excellent oxygen permeability due to the contribution of organopolysiloxane segments. It becomes a great material for sex. It also has advantages in terms of molding, such as excellent solvent solubility and ease of application using coating methods.
Furthermore, it has excellent mechanical strength. On the other hand, even if a polymer has organopolysiloxane segments, it is difficult to form a microphase-separated structure in a polymer that is not regularly incorporated into the main chain, such as a graft copolymer, and its anticoagulant properties are reduced. Not only is it insufficient, but it is also inferior in terms of durability, mechanical strength, etc. In addition, when fluorine-containing segments are not included, durability and biocompatibility are inferior,
If it does not contain an organopolysiloxane segment, it is not preferable because it will be inferior in terms of oxygen permeability and the like. In the present invention, the segment polymer includes radical polymerization of vinyl compounds, ionic polymerization,
Coordination polymerization or polycondensation of difunctional monomers,
Products obtained by various methods such as polyaddition and ring-opening polymerization of epoxide etc. can be used, but the arrangement of the organopolysiloxane segment and the fluorine-containing segment is completely regulated.
Since it is possible to obtain the desired polymer with good reproducibility, polycondensation is performed by applying a chain extender to a prepolymer in which organopolysiloxane segments and fluorine-containing segments are regularly arranged. Polyadducts or polyadducts can be preferably employed. Bonding modes in such suitable segmented polymers include polyurethane, polyurethaneurea, polyurea, polyester, polyamide,
Various forms such as polyamide-imide, polyimide, polycarbonate, and polyether sulfone types can be adopted, but polyurethane, polyurethane urea, and polyurea types are preferable from the viewpoint of polymer durability, mechanical properties, and biocompatibility. The mode of attachment is preferred. Furthermore, it is possible to introduce an oxyalkylene chain as a third segment in order to impart hydrophilicity to the polymer and increase its strength. The oxyalkylene chains are preferably introduced into the polymer by being regularly arranged with fluorine-containing segments instead of organopolysiloxane segments. Such segmented polymers contain as repeating units (a) (-RNHCONHCH 2 R f CH 2 NHCOO-A-OCONHCH 2 R f CH 2 NH
CONH)− and () (b) (−RNHCONHCH 2 R f CH 2 NHCOO−B−CONHCH 2 R f CH 2 NHC
ONH)− (a) (−R−OCONHCH 2 R f CH 2 NHCOO−A−OCONHCH 2 R f CH 2
NHCONH)− and () (b) (−R−OCONHCH 2 R f CH 2 NHCOO−B−CONHCH 2 R f CH 2 N
HCONH)− (a) (−RNHCONHCH 2 R f CH 2 NHCONH−A−NHCONHCH 2 R f CH 2
NHCONH)− and () (b) (−RNHCONHCH 2 R f CH 2 NHCOO−B−CONHCH 2 R f CH 2 NHC
ONH)- and the like are exemplified, among which those represented by the general formula () are particularly suitable from the viewpoints of durability, mechanical properties, availability of raw materials, etc. In the above general formula, R is pear or a divalent organic group having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, specifically ( -CH2 ) -1 (1=1 to 10),

【式】あるいは−CH2(−CF2 )−1CH2−で表わされるものなどが例示される。
またRfは炭素数1〜20、好ましくは1〜10、エ
ーテル結合数0〜10、好ましくは0〜4のバーフ
ルオロアルキレン基であり、具体的には(−CF2)−
,−CF2CF2OCF2CF2−,CF2CF2O(CF2o
OCF2CF2−(n=1〜5),−CF(CF3)O(CF2o
OCF(CF3)−,あるいは−CF2CF2OCF2CF(CF3
O(CF2oOCF(CF3)CF2OCF2CF2−などが例示
される。 上記一般式においてAは、 (ただし、P、Qは炭素数1〜10のアルキレン基
を、また、R1、R2、R3およびR4は炭素数1〜3
のアルキル基または置換アルキル基を示し、nは
1〜50である) であらわされるオルガノポリシロキサンセグメン
ト含有の2価の有機基である。一方、Bは分子量
40〜10000、好ましくは400〜4000のオキシアルキ
レン鎖であるが、1個以上のエステル結合、芳香
環あるいは一部含フツ素アルキレン基などが導入
されてもよい。 具体的には、(−CH2CH2O)−p(p=8〜70)、
(−CH2CH2CH2CH2O)−q(q=5〜42)、〔−CH
(CH3)CH2O〕−r(r=6〜54)、(−CH2CH2O)−a
〔CH(CH3)CH2O〕−b(CH2CH2O)−c(a,c=
1〜5、b=4〜50)、〔−CH2CH2OCO(CH2s
COOCH2CH(CH3)O〕−t(s=1〜5、t=2
〜30)あるいは (u=2〜30)などが例示可能である。 また、該ポリマー中に(a)と(b)がモル比において
1:0〜1:20の割合で含まれることが望まし
い。 本発明において、セグメント化ポリマーの分子
量としては重合体の溶剤溶解性および機械的特性
の両面から、ジメチルホルムアミド中濃度0.5g/
dl、温度30℃で測定される固有粘度(ηinh)が
0.1〜1.5dl/g、特に0.2〜0.9dl/g程度であるも
のが好ましい。 本発明における含フツ素ブロツク重合体は、前
述のごとく種々の方法で製造可能であるが、一例
として前記一般式()の繰返し単位を有する重
合体は一般式 (a′) OCN−CH2RfCH2NHCOO−A−OCONH−CH2RfCH2NC
O および (b′) OCN−CH2RfCH2NHCOO−B−CONHCH2RfCH2NCO (ただし、Rf、A、Bは前記に同じ)で表わさ
れる(a′)、(b′)をモル比1:0〜1:20の割合
で含む含フツ素ジイソシアネートに一般式H2N
−R−NH2(Rは前記に同じ)で表わされるジア
ミンを作用せしめることによつて製造可能であ
る。 本発明の抗凝血性材料は単独の素材として押
出、圧延、キヤステイング、デイツピングあるい
は射出成形などの方法で直接、管、フイルム、シ
ート、あるいは複雑形状品などの形態に成形して
使用できるばかりでなく、被覆材として予め成形
された各種高分子材料、ガラス、金属、セラミツ
クス等に塗布して使用することも可能である。 次に実施例により本発明をさらに具体的に説明
するが、各実施例中において、抗凝血性の評価は
R.I.LeeおよびP.D.Whiteによつて提案された方
法〔Am.J.Med.Sci.、145、495(1913)〕に基いて
行つた。すなわち、セグメントポリマーを50μm
前後の厚さに塗布した内径10mmの試験管2本にヤ
ギの新鮮血各1mlを注ぎ、3分後から一方の試験
管を60秒ごとに傾け、血液が流動しなくなつた時
から他方の試験管に同様の操作を行つて、該試験
管中の血液が該試験管を静かに完全に逆にしても
流動しなくなつた点を終点とし、最初に新鮮血を
注いでから終点までに要した時間を血液凝固時間
とした。また、凝血の終了した試験管を遠心分離
操作にかけ、上層の色調を観察し溶血の有無を調
べた。 さらに、セグメント化ポリマの引張破断強度お
よび伸度は、キヤステイング法により製膜した約
300μ厚の膜を試験片として測定した。ガス透過
性の測定は、50−80μ厚の膜を試験片として製科
研式ガス透過測定装置を用いて行つた。 実施例 1 熱電対、撹拌機および還流管を取りつけた容量
200mlの三口フラスコに窒素雰囲気下で (平均分子量:1250)で現わされるオルガノポリ
シロキサン結合含有ジオール9.31g(7.45m
mol)、酢酸n−ブチル45mlおよび2,2,3,
3,4,4,5,5−オクタフルオロヘキサメチ
レンジイソシアナート〔OCNCH2
(CF24CH2NCO〕4.65g(14.9m mol)をこの
順に仕込んだ。オイルバスで加熱し溶液温度を
120℃に保ち3時間撹拌を続けた後室温まで冷却
することにより、 なる構造を有し、かつmが1であるものを主成分
とするプレポリマーの酢酸−n−ブチル溶液を得
た。 上で得られたプレポリマー溶液に、撹拌しなが
ら酢酸−n−ブチル80mlに溶解したエチレンジア
ミン0.45g(7.5m mol)を、溶液温度が15℃以
下に保たれるような速さで滴下した。滴下終了時
には粘稠な若干白濁した溶液が得られた。さらに
室温で1晩撹拌した後、溶媒を減圧下に留去し
た。乾固した重合体をエタノール、イオン交換水
の順に洗浄後、40℃で真空乾燥してから、再沈法
により精製し、再度40℃で1晩真空乾燥すること
により、白色精製重合体10.37g(収率72%)を
得た。 かくして得られた重合体のN,N−ジメチルホ
ルムアミド中、濃度0.5g/dl、30℃で測定される
固有粘度(ηinh)は0.20dl/gであつた。また、
酸素透過係数P(O2)は28×10-9c.c.−cm/sec−cm2
−cmHg、二酸化炭素透過係数P(CO2)は160×
10-9c.c.−cm/sec−cm2−cmHgであり、Lee−
White法による血液凝固時間は60分以上であつ
た。 実施例 2 実施例1のオルガノポリシロキサン結合含有ジ
オールの使用量を4.66g(3.73m mol)とし、さ
らにポリテトラメチレングリコール(日本ポリウ
レタン工業製PTG200:平均分子量1079)4.02g
(3.73m mol)を混合して使用する以外は実施例
1と同様の操作を行い、白色精製重合体10.47g
(収率76%)を得た。ηinhは0.33dl/gであり、引
張破断強度70Kg/cm2、伸度は480%であつた。ま
た、P(O2)およびP(CO2)はそれぞれ5.7×
10-9c.c.−cm/sec−cm2−cmHgおよび37×10-9c.c.−
cm/sec−cm2−cmHgであり、良好な抗凝血性を示
した。 実施例 3〜5 オルガノポリシロキサン結合含有ジオールと
PTG200の比を変えて、実施例1と同様の方法で
白色精製重合体を得た。結果を表1にまとめた。 なお、実施例1〜5のいずれの場合にもドメイ
ンサイズ約20Å程度のミクロ相分離構造の形成が
観察され、また凝血終了後の溶血はいずれもみと
められなかつた。
Examples include those represented by [Formula] or -CH 2 (-CF 2 )- 1 CH 2 -.
Further, Rf is a barfluoroalkylene group having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, and 0 to 10 ether bonds, preferably 0 to 4 carbon atoms, specifically (-CF 2 )-
1 , −CF 2 CF 2 OCF 2 CF 2 −, CF 2 CF 2 O (CF 2 ) o
OCF 2 CF 2 −(n=1 to 5), −CF(CF 3 )O(CF 2 ) o
OCF (CF 3 ) - or -CF 2 CF 2 OCF 2 CF (CF 3 )
Examples include O( CF2 ) oOCF ( CF3 ) CF2OCF2CF2- . In the above general formula, A is (However, P and Q are alkylene groups having 1 to 10 carbon atoms, and R 1 , R 2 , R 3 and R 4 are 1 to 3 carbon atoms.
represents an alkyl group or a substituted alkyl group, and n is 1 to 50), and is a divalent organic group containing an organopolysiloxane segment. On the other hand, B is the molecular weight
It has an oxyalkylene chain of 40 to 10,000, preferably 400 to 4,000, but one or more ester bonds, aromatic rings, or some fluorine-containing alkylene groups may be introduced. Specifically, ( -CH2CH2O ) -p (p = 8 to 70),
(−CH 2 CH 2 CH 2 CH 2 O) − q (q=5 to 42), [−CH
(CH 3 ) CH 2 O] − r (r = 6 to 54), (−CH 2 CH 2 O) − a
[CH (CH 3 ) CH 2 O] − b (CH 2 CH 2 O) − c (a, c=
1 to 5, b=4 to 50), [ -CH2CH2OCO ( CH2 ) s
COOCH 2 CH(CH 3 )O〕 −t (s=1~5, t=2
~30) or (u=2 to 30), etc. can be exemplified. Further, it is desirable that the polymer contains (a) and (b) in a molar ratio of 1:0 to 1:20. In the present invention, the molecular weight of the segmented polymer is determined to be 0.5 g/concentration in dimethylformamide from both the solvent solubility and mechanical properties of the polymer.
dl, the intrinsic viscosity (ηinh) measured at a temperature of 30℃ is
It is preferably about 0.1 to 1.5 dl/g, particularly about 0.2 to 0.9 dl/g. The fluorine-containing block polymer of the present invention can be produced by various methods as described above, but as an example, a polymer having a repeating unit of the general formula () has the general formula (a') OCN-CH 2 R f CH 2 NHCOO−A−OCONH−CH 2 R f CH 2 NC
(a'), (b') represented by O and (b') OCN-CH 2 R f CH 2 NHCOO-B-CONHCH 2 R f CH 2 NCO (where Rf, A, and B are the same as above) The general formula H 2 N is added to the fluorine-containing diisocyanate containing in a molar ratio of 1:0 to 1:20.
It can be produced by reacting with a diamine represented by -R-NH 2 (R is the same as above). The anticoagulant material of the present invention can be used as a single raw material by directly forming it into a tube, film, sheet, or complex-shaped product by extrusion, rolling, casting, dipping, injection molding, or other methods. It is also possible to use it as a covering material by applying it to various pre-formed polymer materials, glass, metals, ceramics, etc. Next, the present invention will be explained in more detail with reference to Examples. In each Example, the evaluation of anticoagulability was
The method was based on the method proposed by RILee and PD White [Am.J.Med.Sci., 145 , 495 (1913)]. That is, the segment polymer is 50μm
Pour 1 ml of fresh goat blood into two test tubes with an inner diameter of 10 mm coated on the front and back. After 3 minutes, tilt one test tube every 60 seconds, and when the blood stops flowing, pour the other test tube. Perform the same operation on the test tube, and the end point is the point at which the blood in the test tube no longer flows even when the test tube is gently completely reversed. The time required was defined as the blood coagulation time. In addition, the test tubes in which the blood had coagulated were centrifuged, and the color tone of the upper layer was observed to determine the presence or absence of hemolysis. Furthermore, the tensile breaking strength and elongation of the segmented polymer were approximately
Measurements were made using a 300μ thick film as a test piece. Gas permeability was measured using a Seikagaku-style gas permeation measuring device using a 50-80 μm thick membrane as a test piece. Example 1 Capacity with thermocouple, stirrer and reflux tube installed
in a 200 ml three-necked flask under nitrogen atmosphere. (average molecular weight: 1250) 9.31 g (7.45 m
mol), 45 ml of n-butyl acetate and 2,2,3,
3,4,4,5,5-octafluorohexamethylene diisocyanate [OCNCH 2
(CF 2 ) 4 CH 2 NCO] 4.65 g (14.9 mmol) were charged in this order. Heat in an oil bath to adjust the solution temperature.
By keeping it at 120℃ and stirring for 3 hours, cooling it to room temperature. An n-butyl acetate solution of a prepolymer having the following structure and having m as 1 as a main component was obtained. To the prepolymer solution obtained above, while stirring, 0.45 g (7.5 mmol) of ethylenediamine dissolved in 80 ml of n-butyl acetate was added dropwise at such a rate that the solution temperature was maintained below 15°C. At the end of the dropwise addition, a viscous and slightly cloudy solution was obtained. After further stirring at room temperature overnight, the solvent was distilled off under reduced pressure. The dried polymer was washed with ethanol and ion-exchanged water in that order, then vacuum-dried at 40℃, purified by reprecipitation method, and vacuum-dried again at 40℃ overnight to obtain 10.37g of white purified polymer. (yield 72%). The intrinsic viscosity (ηinh) of the thus obtained polymer measured in N,N-dimethylformamide at a concentration of 0.5 g/dl at 30°C was 0.20 dl/g. Also,
The oxygen permeability coefficient P (O 2 ) is 28×10 -9 cc-cm/sec-cm 2
-cmHg, carbon dioxide permeability coefficient P (CO 2 ) is 160×
10 -9 cc−cm/sec−cm 2 −cmHg, and Lee−
Blood coagulation time by White method was over 60 minutes. Example 2 The amount of the organopolysiloxane bond-containing diol used in Example 1 was 4.66 g (3.73 mmol), and 4.02 g of polytetramethylene glycol (PTG200 manufactured by Nippon Polyurethane Industries: average molecular weight 1079) was added.
The same operation as in Example 1 was carried out except that (3.73 m mol) was mixed and used, and 10.47 g of white purified polymer was obtained.
(yield 76%). ηinh was 0.33 dl/g, tensile strength at break was 70 Kg/cm 2 , and elongation was 480%. Also, P(O 2 ) and P(CO 2 ) are each 5.7×
10 -9 cc−cm/sec−cm 2 −cmHg and 37×10 −9 cc−
cm/sec- cm2 -cmHg, indicating good anticoagulability. Examples 3-5 Organopolysiloxane bond-containing diol and
A white purified polymer was obtained in the same manner as in Example 1 except that the ratio of PTG200 was changed. The results are summarized in Table 1. In addition, in all of Examples 1 to 5, the formation of a microphase-separated structure with a domain size of approximately 20 Å was observed, and no hemolysis after completion of coagulation was observed in any of them.

【表】【table】

Claims (1)

【特許請求の範囲】 1 オルガノポリシロキサンセグメントと含フツ
素セグメントが、主鎖に規則的に組込まれたセグ
メント化ポリマーからなることを特徴とする抗凝
血性材料。 2 セグメント化ポリマーが、第三セグメントと
して主鎖にオキシアルキレン鎖を含む第1項記載
の材料。 3 セグメント化ポリマーが、ポリウレタン及び
ポリウレタンウレア型から選ばれる結合様式を有
する第1項および第2項記載の材料。 4 セグメント化ポリマーが (a) −RNHCONHCH2RfCH2NHCOO−A−OCONHCH2RfCH2NHCO
NH−及び (b) −RNHCONHCH2RfCH2NHCOO−B−CONHCH2RfCH2NHCON
H− (但し、RはナシあるいはC1〜C20の2価の有機
基を、RfはC1〜C20、エーテル結合数0〜10のパ
ーフルオロアルキレン基を表わし、Aは 〔ただし、P、Qは炭素数1〜10のアルキレン基
を、またR1、R2、R3およびR4は炭素数1〜3の
アルキル基または置換アルキル基を示し、nは1
〜50である〕を、また、Bは、分子量40〜10000
のオキシアルキレン基を表わす) を構成単位とし、かつモル比において (a):(b)=1:0〜1:20 の割合で含有する第3項記載の材料。 5 オルガノポリシロキサンセグメント含量がポ
リマーの10〜80重量%である酸素透過性の良好な
第4項記載の材料。 6 オルガノポリシロキサンセグメント含量がポ
リマーの40〜70重量%である第5項記載の材料。
[Scope of Claims] 1. An anticoagulant material comprising a segmented polymer in which organopolysiloxane segments and fluorine-containing segments are regularly incorporated into the main chain. 2. The material according to item 1, wherein the segmented polymer contains an oxyalkylene chain in the main chain as the third segment. 3. Material according to paragraphs 1 and 2, in which the segmented polymer has a bonding mode selected from polyurethane and polyurethaneurea types. 4 The segmented polymer is (a) -RNHCONHCH 2 R f CH 2 NHCOO-A-OCONHCH 2 R f CH 2 NHCO
NH− and (b) −RNHCONHCH 2 R f CH 2 NHCOO−B−CONHCH 2 R f CH 2 NHCON
H- (However, R is pear or a C 1 to C 20 divalent organic group, R f is a C 1 to C 20 perfluoroalkylene group with 0 to 10 ether bonds, and A is [However, P and Q represent an alkylene group having 1 to 10 carbon atoms, R 1 , R 2 , R 3 and R 4 represent an alkyl group or substituted alkyl group having 1 to 3 carbon atoms, and n is 1
50], and B has a molecular weight of 40 to 10,000
(representing an oxyalkylene group) as a constitutional unit, and the material is contained in a molar ratio of (a):(b)=1:0 to 1:20. 5. The material according to item 4, which has good oxygen permeability and has an organopolysiloxane segment content of 10 to 80% by weight of the polymer. 6. The material of claim 5, wherein the organopolysiloxane segment content is from 40 to 70% by weight of the polymer.
JP57138019A 1982-08-10 1982-08-10 Anti-thrombotic material Granted JPS5928968A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57138019A JPS5928968A (en) 1982-08-10 1982-08-10 Anti-thrombotic material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57138019A JPS5928968A (en) 1982-08-10 1982-08-10 Anti-thrombotic material

Publications (2)

Publication Number Publication Date
JPS5928968A JPS5928968A (en) 1984-02-15
JPH0224543B2 true JPH0224543B2 (en) 1990-05-29

Family

ID=15212150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57138019A Granted JPS5928968A (en) 1982-08-10 1982-08-10 Anti-thrombotic material

Country Status (1)

Country Link
JP (1) JPS5928968A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61206456A (en) * 1985-03-09 1986-09-12 泉工医科工業株式会社 Antithrombotic membrane type artificial lung
JP6075498B1 (en) * 2015-08-07 2017-02-08 ダイキン工業株式会社 Composition, coating film, fluorine-containing coating film and laminate

Also Published As

Publication number Publication date
JPS5928968A (en) 1984-02-15

Similar Documents

Publication Publication Date Title
US5221724A (en) Polysiloxane polyurea urethanes
JPS5841563A (en) Anti-coagulant material of blood
US4523005A (en) Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4528343A (en) Antithrombogenic elastomer, molded products of the same, and a process for manufacturing the same
JP4067564B2 (en) Block copolymer
US4861830A (en) Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming
Takahara et al. Effect of surface hydrophilicity on ex vivo blood compatibility of segmented polyurethanes
Chapman et al. Determination of low critical surface tensions of novel fluorinated poly (amide urethane) block copolymers. 2. Fluorinated soft-block backbone and side chains
US20060183871A1 (en) Biosensor membrane material
JPS61200114A (en) Antithrombotic polyurethane compound and production thereof
JPH02180920A (en) New siloxane-urethane polymer and contact lens made thereof
JPS6251131B2 (en)
JPS62527A (en) Polyamide copolymer
US5798437A (en) Thermoplastic block copolymers
JPS5987004A (en) Gas separation membrane
JPH0224543B2 (en)
JPH10505108A (en) Hydrophilic polyurethane
Matsumoto et al. Novel functional polymers: Poly (dimethylsiloxane)–polyamide multiblock copolymer. IV. Gas permeability and thermomechanical properties of aramid–silicone resins
CN1535993A (en) Block hydrophobic/oleophobic polyether polyurethane copolymer and its preparation method and use
Kawakami et al. Synthesis and gas permeability of aromatic polyamide and polyimide having oligodimethylsiloxane in main-chain or in side-chain
JPH0753764A (en) Production of porous polyurethaneurea film for medical use
JPH0149408B2 (en)
JPS58188458A (en) Anti-thrombotic elastomer, production thereof and molded body comprising same
JP2604844B2 (en) Anticoagulant material
JPH06184266A (en) Antithrombogenic polyurethane elastomer and medical tool